Cuprina Holdings (Cayman) Limited competitors & alternatives

Similar biotechnology company

Tiger BioSciences is a medical technology company that specializes in regenerative medicine, developing cellular, acellular, and matrix-like products for wound care and aesthetic treatments. The company also manages human tissue recovery programs to supply biological materials for clinical applications. It serves healthcare providers and medical professionals globally.

CollPlant Biotechnologies Ltd.CLGN · BiotechnologyRehovot, Israel

64% matchPublic

Similar biotechnology company

CollPlant Biotechnologies Ltd. is a biotechnology company headquartered in Rehovot, Israel. The company focuses on regenerative medicine and reports its financial results in U.S. dollars.

Similar biotechnology company

Giant Biogene Holding Co., Ltd. operates as an investment holding entity, primarily engaged in the research, development, production, and sale of beauty and wellness products based on bioactive materials throughout the People's Republic of China. The company also manufactures functional foods leveraging rare ginsenosides technology and provides medical devices. Its diverse product range, which includes specialized skincare, medical dressings, and nutritional supplements, is marketed predominantly under brand names such as Comfy, Collgene, Keyu, Kehen, Kefuping, Leeyen, SKIGIN, and Shengan. Established in 2000, Giant Biogene Holding Co., Ltd. maintains its headquarters in Xi'an, PRC.

Biotech

Ondine Biomedical Inc., a life sciences firm, specializes in the research, development, and commercialization of advanced antimicrobial photodisinfection therapies, operating both within Canada and internationally. Its foundational technology is Photodisinfection, a state-of-the-art, light-based topical antimicrobial approach designed to neutralize detrimental pathogens. The company's flagship product, Steriwave, is a medical device leveraging photodisinfection to eradicate harmful nasal pathogens, thereby significantly mitigating healthcare-acquired infections. Furthermore, Ondine Biomedical's development pipeline includes a topical antiviral treatment for the upper respiratory tract aimed at reducing SARS-CoV-2 viral load and transmission; a solution for addressing chronic rhinosinusitis; OND1002, an agent for disinfecting endotracheal tubes to decrease the occurrence of ventilator-associated pneumonia; and OND1003, formulated for the decolonization of burns and wounds. Established in 1996, the company maintains its corporate headquarters in Vancouver, Canada.

サイフューズ4892 · BiotechTokyo, Japan

63% matchPublic

Biotech

Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic regeneration, and it also undertakes contract work for cellular product research and development. Furthermore, Cyfuse Biomedical offers advanced Bio 3D Printers, which are instrumental in regenerating a variety of tissues and organs, including cartilage, bones, blood vessels, and nerves. Their specialized equipment includes 'regenova,' a bio 3D printer enabling three-dimensional cell stacking, and 'S-PIKE,' designed for forming complex 3D structures from cells.

Eterna RegenerativesBiotechnologyUnited Kingdom

63% match

Similar biotechnology company

Eterna Regeneratives develops regenerative biomaterials and protein-derived scaffolds designed for mineralisation and tissue regeneration. The company's initial applications focus on oral health and enamel repair through professional consumer dental care formats, as well as bone regeneration for orthopaedic and bone grafting uses.

Organogenesis Holdings Inc.ORGO · BiotechCanton, United States

63% matchPublic

Biotech

Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.

Biotech

Shanghai Haohai Biological Technology Co., Ltd. is a global enterprise dedicated to the research, development, manufacturing, and commercialization of biomedical materials. Its operations span Mainland China, the United States, the United Kingdom, and various other international regions. A comprehensive product portfolio addresses several key medical disciplines. Within ophthalmology, offerings include intraocular lenses, ophthalmic viscoelastic devices, orthokeratology and phakic refractive lenses, eye drops, injectors, and surgical scalpels. Orthopedics products encompass sodium hyaluronate injections and medical chitosan. For wound repair, it manufactures recombinant human epidermal growth factor, effective in treating burn wounds, residual wounds, donor site post-traumatic wounds, and both fresh and chronic ulcerations. Additionally, the company develops anti-adhesion materials, including medical sodium hyaluronate gel and medical chitosan, as well as hemostatic solutions such as collagen sponges and porcine fibrin sealants. Beyond its therapeutic offerings, Shanghai Haohai maintains a significant presence in the medical aesthetics market. This segment features a range of hyaluronic acid (HA) dermal fillers: Matrifill, positioned as a first-generation mono-phase injectable HA gel; Janlane, a second-generation filler engineered for dynamic application; and Hyalumatrix, a third-generation product providing precise aesthetic embellishment. Its aesthetic portfolio is further complemented by radio frequency devices and laser equipment. Furthermore, the company actively engages in the research and development of biological engineering and pharmaceutical products, extending services such as technology transfer and consultation. It also conducts investment and trading operations. Established in 2007, the entity initially traded as Haohai Limited before officially adopting the name Shanghai Haohai Biological Technology Co., Ltd. in 2010. Its corporate headquarters are based in Shanghai, China.

Biotech

Shanghai Haohai Biological Technology Co., Ltd. is a global enterprise specializing in the research, development, manufacturing, and distribution of advanced biomedical materials. Its operations span Mainland China, the United States, the United Kingdom, and various international markets. The company's extensive product portfolio serves multiple medical fields. For ophthalmology, offerings include intraocular lenses, ophthalmic viscoelastic devices, specialized orthokeratology and phakic refractive lenses, eye drops, injectors, and surgical scalpels. In orthopedics, they provide sodium hyaluronate injections and medical chitosan. Their wound care segment features recombinant human epidermal growth factor, effective in treating a broad spectrum of injuries, including burns, residual wounds, donor site trauma, post-traumatic wounds, and both acute and chronic ulcerations. Anti-adhesion solutions are offered in the form of medical sodium hyaluronate gel and medical chitosan, while hemostatic products include collagen sponges and porcine fibrin sealants. Within medical aesthetics, Shanghai Haohai produces a diverse range of hyaluronic acid (HA) dermal fillers: Matrifill, a first-generation mono-phase injectable gel; Janlane, a second-generation filler engineered for dynamic applications; and Hyalumatrix, a third-generation product designed for precise aesthetic enhancements. This division also supplies radio frequency devices and laser equipment. Beyond its core product offerings, the company actively pursues research and development in biological engineering and pharmaceutical innovations. It also provides related technology transfer and consultation services, alongside engaging in investment and trading activities. Originally established in 2007 as Haohai Limited, the company adopted its current name, Shanghai Haohai Biological Technology Co., Ltd., in 2010 and is headquartered in Shanghai, China.

Similar biotechnology company

Operating from its Tokyo headquarters, Cytori Cell Research Institute, Inc., established in 2004 (originally FRACTALE Corporation), specializes in the comprehensive research, development, production, and distribution of medical devices related to cell therapy throughout Japan. The company offers various cell therapy kits and continuously advances cellular treatment technologies through ongoing research and development. Its active development pipeline includes ECCI-50, designed for the treatment of male stress urinary incontinence and hepatic cirrhosis, and Cyt-006, formulated to prevent postoperative adhesion after primary rectal cancer surgery. Additionally, Cytori conducts extensive clinical trials and investigations into cell-based therapies for a wide array of conditions and applications, such as the repair of anterior cruciate ligaments and bones, burn scar remediation, chronic wound healing, critical limb ischemia, treatment of anal and Crohn's disease fistulas, and erectile dysfunction. Beyond its primary biotechnological focus, the company also participates in the real estate sector, encompassing investment, ownership, development, leasing, and management of properties and hotels, as well as providing real estate brokerage services.

Biotech

Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.

Biotech

Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market. Central to their offerings is a technology that isolates components from a patient's own blood (autologous) to generate a platelet-based therapy, specifically tailored for the treatment of chronic wounds. Established in Houston, Texas, in 1998, the company underwent a name change from Cytomedix, Inc. to Nuo Therapeutics, Inc. in November 2014.